Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
3.750
-0.090 (-2.34%)
At close: Jun 27, 2025, 4:00 PM
3.770
+0.020 (0.53%)
After-hours: Jun 27, 2025, 4:00 PM EDT
Genfit Employees
Genfit had 180 employees as of December 31, 2024. The number of employees increased by 21 or 13.21% compared to the previous year.
Employees
180
Change (1Y)
21
Growth (1Y)
13.21%
Revenue / Employee
$406,598
Profits / Employee
$8,668
Market Cap
203.47M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GNFT News
- 10 days ago - GENFIT: June 17, 2025 Combined Shareholders Meeting Results - GlobeNewsWire
- 5 weeks ago - GENFIT Reports First Quarter 2025 Financial Information - GlobeNewsWire
- 5 weeks ago - GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy - GlobeNewsWire
- 6 weeks ago - GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) - GlobeNewsWire
- 7 weeks ago - GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents - GlobeNewsWire
- 7 weeks ago - GENFIT to Present Latest ACLF Research at EASL Congress 2025 - GlobeNewsWire
- 2 months ago - GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F - GlobeNewsWire
- 2 months ago - GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 - GlobeNewsWire